For more on David Nierengarten’s comments: Karyopharm stock is soaring for a second day on a key FDA approval
David Nierengarten: Approval Marks a Favorable Ending to a Roller Coaster Regulatory Ride
For more on David Nierengarten’s comments: Karyopharm stock is soaring for a second day on a key FDA approval